AIM ImmunoTech publishes investor presentation on Ampligen’s potential in pancreatic cancer
AIM•AIM ImmunoTech published a presentation outlining potential uses of Ampligen in pancreatic cancer, including combination treatment and maintenance therapy. Phase 2 DURIPANC topline results are expected in Q1 2027, with additional analyses anticipated in Q3 2027; safety and efficacy remain unestablished.
1. Presentation outlines plans
AIM ImmunoTech published an investor presentation exploring the potential of adding Ampligen to daraxonrasib treatment or using Ampligen as maintenance therapy for pancreatic cancer. Safety and efficacy remain unestablished. Phase 2 DURIPANC topline results are expected in Q1 2027, with additional clinical and immune-response analyses anticipated in Q3 2027.
